{
    "title": "Biogen profit beats on surprisingly strong Spinraza sales",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4443494/Biogen-revenue-profit-beat-Street-strong-Spinraza-launch.html",
    "date": "2017-04-25",
    "keywords": [
        "drug",
        "estimate",
        "percent",
        "spinraza",
        "company",
        "grover",
        "atrophy",
        "tecfidera",
        "smt",
        "year",
        "consensus",
        "cowen",
        "officer",
        "call",
        "launch",
        "vounatsos",
        "biogen",
        "tysabri",
        "agreement",
        "share",
        "roche",
        "revenue",
        "profit",
        "spinrazas",
        "robust",
        "demand",
        "companys",
        "trading",
        "firstofitskind",
        "medicine",
        "food",
        "administration",
        "cause",
        "death",
        "injection",
        "use",
        "survey",
        "majority",
        "therapy",
        "yearend",
        "co",
        "paul",
        "clancy",
        "conference",
        "adoption",
        "insurance",
        "treatment",
        "michel",
        "george",
        "scangos",
        "eu",
        "japan",
        "canada",
        "marketing",
        "sclerosis",
        "health",
        "regulator",
        "bestseller",
        "street",
        "ms",
        "market",
        "quarter",
        "partowner",
        "royalty",
        "thomson",
        "q1",
        "performance",
        "pace",
        "guidance",
        "reporting",
        "bengaluru",
        "editing",
        "sriraj",
        "kalluvila"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}